Gordon Fraser Shares New Insights on Triple Lipid Complex Supporting Skin Barrier Function and Moisture Retention

New insights from Gordon Fraser spotlight a Triple Lipid Complex that supports skin barrier function, hydration, and ...
verywellhealth

6 Types of Treatment for Complement 3 Glomerulopathy

Complement 3 glomerulopathy (C3G) is a rare kidney disease that is also considered an autoimmune disorder. There is no single cure for C3G, but several treatments may slow disease progression, protect ...
verywellhealth

How Complement 3 Glomerulopathy Is Diagnosed: Step-by-Step

Complement 3 glomerulopathy (C3G) is diagnosed with a combination of a clinical evaluation, blood tests, urine tests, and a renal (kidney) biopsy. The only way to definitively diagnose C3G and its ...
Pharmabiz

Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy

Omeros Corporation, an innovative biotechnology company, announced that the US Food and Drug Administration (FDA) has approved Yartemlea (narsoplimab-wuug) for the treatment of hematopoietic stem cell ...
Seeking Alpha

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of hematopoietic ...
MarketWatch

FDA Approves Omeros' YARTEMLEA(R) -- First and Only Therapy Indicated for TA-TMA

The MarketWatch News Department was not involved in the creation of this content. -- Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: ...
Nasdaq

Omeros Wins FDA Approval For YARTEMLEA In Transplant-Associated Thrombotic Microangiopathy

(RTTNews) - Omeros Corporation (OMER) today announced that the FDA has approved YARTEMLEA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and ...
MarketWatch

Omeros Gets FDA Approval of Yartemlea

Omeros has won U.S. Food and Drug Administration approval of its Yartemlea treatment for an often-fatal complication of stem-cell transplants. Omeros on Wednesday said the approval covers Yartemlea ...
grafa

Omeros surges as FDA clears Yartemlea as first-ever stem cell complication therapy

Omeros Corporation (NASDAQ:OMER) said the U.S. Food and Drug Administration approved YARTEMLEA (narsoplimab-wuug) to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy, ...
WebMD

What Is Complement 3 Glomerulopathy?

Also called C3G, this rare kidney disease often affects children and young adults, but it can happen at any age. It has a major impact on a person’s health and life. C3G has two forms: dense deposit ...
BioWorld

CTX-114 enhances surface binding and function of complement factor H

Among the most significant genetic risk factors for age-related macular degeneration is the Y402H variant of complement factor H, which, along with its splice isoform FHL-1, impairs binding to the ...